Metropolis Healthcare Ltd, a leading diagnostics service provider, continued its strong momentum in the March quarter, reporting a 23% year-on-year growth in consolidated revenues (provisional and unaudited).
The performance was driven by sustained traction in the TruHealth wellness segment and specialised testing, along with robust growth across both B2B and B2C channels.
Broad-based growth across segments
During the quarter, revenue growth of 23% included contributions from core operations as well as acquisitions such as Core Diagnostics, Scientific Pathology, Dr Ahuja Pathology and Imaging Centre (DAPIC) and Dr RS Patil Ambika Pathology Laboratory (Ambika).
B2C revenue grew 19% year-on-year, while B2B revenue recorded a stronger 30% growth, supported by higher contribution from core diagnostics and specialty testing.
The TruHealth wellness segment and specialty diagnostics segment registered growth of 25% and 29%, respectively.
Integration benefits from acquisitions
MHL said acquisitions completed last year are progressing well, with integration efforts and synergy benefits beginning to translate into tangible outcomes.
Margins in the core diagnostics segment improved to the high single-digit range, while DAPIC, Scientific and Ambika continued to deliver margins higher than the company’s average.
Organic growth remains healthy
MHL’s organic business recorded revenue growth of 14.5%, driven by increased patient volumes, higher test volumes and an improved product mix.
EBITDA margins for the quarter also improved on a year-on-year basis, supported by operating leverage and efficiency gains across operations.
Nine-month performance remains strong
For the nine-month period ended December 2025, the group reported a 24% growth in revenues, while organic revenue growth stood at 13%.
The steady performance reflects disciplined execution across business segments, supported by balanced volume expansion and an improving test mix.
MHL said that its group’s reported numbers include contributions from four acquisitions – Core Diagnostics, DAPIC (Dehradun), Scientific Pathology (Agra) and Ambika Diagnostics (Kolhapur), while organic growth excludes these entities.